RobertAndrewSiskMDFACS, FASRS
Ophthalmology • Blue Ash, OHPediatric & Strabismus, Retinal Disease, Uveitis
Associate Professor, Ophthalmology, University of Cincinnati College of Medicine
Dr. Sisk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1945 CEI Drive
Cincinnati Eye Institute
Blue Ash, OH 45242Phone+1 513-984-5133Fax+1 513-569-3875
Summary
- Dr. Robert Sisk is an ophthalmologist in Blue Ash, OH and is affiliated with multiple hospitals in the area, including St Elizabeth Covington, Cincinnati Children's Hospital Medical Center, Bethesda North Hospital, and Good Samaritan Hospital. He received his medical degree from University of Kentucky College of Medicine and has been in practice 14 years. He specializes in pediatric & strabismus, retinal disease, and uveitis and is experienced in diabetes mellitus, stickler syndrome, optical coherence tomography, pediatric ophthalmology, and medical genetics.
Education & Training
University of Cincinnati Medical Center/College of MedicineResidency, Ophthalmology, 2004 - 2007- University of Cincinnati Medical Center/College of MedicineInternship, Internal Medicine, 2003 - 2004
University of Kentucky College of MedicineClass of 2003
Certifications & Licensure
OH State Medical License 2003 - 2026
KY State Medical License 2009 - 2025
FL State Medical License 2007 - 2019- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Treatment for Presumed Ocular Histoplasmosis Start of enrollment: 2013 Mar 01
Publications & Presentations
PubMed
- Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results: Subretinal Gene Therapy AGTC-501 for XLRP P...Paul Yang, David Birch, Andreas Lauer, Robert Sisk, Rajiv Anand
American Journal of Ophthalmology. 2024-12-04 - Real-World Long-Term Outcomes of Intravitreal Faricimab in Previously Treated Chronic Neovascular Age-Related Macular Degeneration.Naveen R Ambati, Adam Leone, Daniel Brill, Robert A Sisk
Retina. 2024-11-11 - 1 citationsUltrawidefield Fluorescein Angiography and OCT Findings in Children and Young Adults with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy.Jared J Ebert, Ilaria Maccora, Camera C Sapp, Tiffany Nguyen, Robert A Sisk
Ophthalmology. Retina. 2024-11-01
Press Mentions
AGTC to Host Virtual R&D Day on July 22, 2021July 8th, 2021- AGTC Reports Positive 12-Month Data from Highest Dose Groups in Its Ongoing XLRP Phase 1/2 Clinical TrialMay 6th, 2021
- AGTC Reports Positive 12-Month Data from Highest Dose Groups in Its Ongoing XLRP Phase 1/2 Clinical TrialMay 6th, 2021
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
